{"transactions":[{"id":2502552,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Restricted Stock Unit  Award","published_at":"2021-11-19T09:56:54.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":106100,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"At the effective time of the Merger, each outstanding restricted stock unit award conditioned on performance metrics (\"PSU\") was accelerated (assuming achievement at 100% of the applicable target levels) and became fully vested and cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such PSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"At the effective time of the Merger, each outstanding restricted stock unit award conditioned on performance metrics (\"PSU\") was accelerated (assuming achievement at 100% of the applicable target levels) and became fully vested and cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such PSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"At the effective time of the Merger, each outstanding restricted stock unit award conditioned on performance metrics (\"PSU\") was accelerated (assuming achievement at 100% of the applicable target levels) and became fully vested and cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such PSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"At the effective time of the Merger, each outstanding restricted stock unit award conditioned on performance metrics (\"PSU\") was accelerated (assuming achievement at 100% of the applicable target levels) and became fully vested and cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such PSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":106100},"source":{"system":"sec-edgar","filing":"0001209191-21-065703","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065703/doc4.xml","form_type":"4"}},{"id":2502551,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-19T09:56:54.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":185000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":15.78,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":185000},"source":{"system":"sec-edgar","filing":"0001209191-21-065703","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065703/doc4.xml","form_type":"4"}},{"id":2502550,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-19T09:56:54.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":290000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":14.75,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":290000},"source":{"system":"sec-edgar","filing":"0001209191-21-065703","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065703/doc4.xml","form_type":"4"}},{"id":2502549,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-19T09:56:54.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":116667,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":22.31,"expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":116667},"source":{"system":"sec-edgar","filing":"0001209191-21-065703","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065703/doc4.xml","form_type":"4"}},{"id":2502548,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-19T09:56:54.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":175000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":18.56,"expiration_date":"2026-12-19","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-21-065703","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065703/doc4.xml","form_type":"4"}},{"id":2502547,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-19T09:56:54.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":155000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":18.2,"expiration_date":"2026-01-03","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001209191-21-065703","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065703/doc4.xml","form_type":"4"}},{"id":2502546,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-19T09:56:54.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":110000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":22.91,"expiration_date":"2025-01-20","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-21-065703","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065703/doc4.xml","form_type":"4"}},{"id":2502545,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-19T09:56:54.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":17.61,"expiration_date":"2024-03-02","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-21-065703","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065703/doc4.xml","form_type":"4"}},{"id":2502544,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-19T09:56:54.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":136530,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements."}],"balance_after":0,"derivative":{"exercise_price":2.52,"expiration_date":"2023-07-18","underlying":"Common Stock","underlying_shares":136530},"source":{"system":"sec-edgar","filing":"0001209191-21-065703","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065703/doc4.xml","form_type":"4"}},{"id":2502543,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-11-19T09:56:54.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":388683,"price":8.5,"value":3303805.5,"ownership":{"direct":false,"nature":"By Versant Development Fund III, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. (\"Issuer\"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. (\"Purchaser\") (\"Merger Agreement\"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation (\"Merger\"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash (\"Cash Amount\"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 (\"CVR Payments\"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Development Fund III, LLC.  The Reporting Person is a manager and minority member of Versant Development Fund III, LLC.  The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-065703","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065703/doc4.xml","form_type":"4"}},{"id":2502542,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-11-19T09:56:54.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":24600,"price":8.5,"value":209100.0,"ownership":{"direct":false,"nature":"By the Michael D. Clayman Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. (\"Issuer\"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. (\"Purchaser\") (\"Merger Agreement\"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation (\"Merger\"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash (\"Cash Amount\"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 (\"CVR Payments\"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-065703","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065703/doc4.xml","form_type":"4"}},{"id":2502541,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-11-19T09:56:54.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":373769,"price":8.5,"value":3177036.5,"ownership":{"direct":false,"nature":"By the Michael D.Clayman 2006 Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. (\"Issuer\"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. (\"Purchaser\") (\"Merger Agreement\"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation (\"Merger\"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash (\"Cash Amount\"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 (\"CVR Payments\"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-065703","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065703/doc4.xml","form_type":"4"}},{"id":2502540,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-11-19T09:56:54.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":335498,"price":8.5,"value":2851733.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. (\"Issuer\"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. (\"Purchaser\") (\"Merger Agreement\"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation (\"Merger\"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash (\"Cash Amount\"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 (\"CVR Payments\"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 517 shares of Issuer common stock acquired under the Issuer's 2013 Employee Stock Purchase Plan on November 17, 2021."},{"field":"shares","element":"transactionShares","label":"F3","text":"At the effective time of the Merger, each outstanding restricted stock unit award (\"RSU\") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-065703","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065703/doc4.xml","form_type":"4"}},{"id":2629158,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-07-20T20:44:14.000Z","date":"2021-07-19","kind":"tax_withholding","acquired":false,"shares":13859,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on July 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on July 16, 2020."}],"balance_after":334981,"source":{"system":"sec-edgar","filing":"0001209191-21-047501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121047501/doc4.xml","form_type":"4"}},{"id":2653281,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-06-28T18:04:37.000Z","date":"2021-06-21","kind":"grant","acquired":true,"shares":1700,"price":7.78,"value":13226.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed voluntarily to report the acquisition of 1,700 shares by the Reporting Person on June 21, 2021, pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":348840,"source":{"system":"sec-edgar","filing":"0001209191-21-043522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121043522/doc4.xml","form_type":"4"}},{"id":2774551,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-23T19:01:30.000Z","date":"2021-02-01","kind":"gift","acquired":false,"shares":21099,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 1, 2021, the Reporting Person transferred 21,099 shares of the Issuer's Common Stock to The Michael D. Clayman 2006 Revocable Trust."}],"balance_after":347140,"source":{"system":"sec-edgar","filing":"0001209191-21-022677","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121022677/doc4.xml","form_type":"4"}},{"id":2774550,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-23T19:01:30.000Z","date":"2021-01-08","kind":"gift","acquired":false,"shares":4762,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 8, 2021, the Reporting Person transferred 4,762 shares of the Issuer's Common Stock to The Michael D.Clayman 2006 Revocable Trust."}],"balance_after":368239,"source":{"system":"sec-edgar","filing":"0001209191-21-022677","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121022677/doc4.xml","form_type":"4"}},{"id":2812627,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Restricted Stock Unit Award","published_at":"2021-03-03T18:16:38.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":159150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the maximum number of shares deliverable under the performance restricted stock unit award."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon confirmation by the Board of Directors or the Compensation Committee thereof that a specified amount of 2021 revenues from ZILRETTA product sales and certain clinical development milestones are achieved, 25% of the shares eligible for vesting under the restricted stock unit award shall vest in 2022 upon confirmation of such performance metrics being achieved and thereafter on January 1 of the subsequent three years so that all of such shares will have vested on January 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon confirmation by the Board of Directors or the Compensation Committee thereof that a specified amount of 2021 revenues from ZILRETTA product sales and certain clinical development milestones are achieved, 25% of the shares eligible for vesting under the restricted stock unit award shall vest in 2022 upon confirmation of such performance metrics being achieved and thereafter on January 1 of the subsequent three years so that all of such shares will have vested on January 1, 2025."}],"balance_after":159150,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":159150},"source":{"system":"sec-edgar","filing":"0001209191-21-017207","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121017207/doc4.xml","form_type":"4"}},{"id":2812626,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-03T18:16:38.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":106100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan."}],"balance_after":373001,"source":{"system":"sec-edgar","filing":"0001209191-21-017207","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121017207/doc4.xml","form_type":"4"}},{"id":2890150,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-29T20:17:11.000Z","date":"2021-01-28","kind":"tax_withholding","acquired":false,"shares":8776,"price":12.37,"value":108559.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on March 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on March 2, 2020."}],"balance_after":266901,"source":{"system":"sec-edgar","filing":"0001209191-21-006328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121006328/doc4.xml","form_type":"4"}},{"id":2890149,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-29T20:17:11.000Z","date":"2021-01-27","kind":"grant","acquired":true,"shares":119500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 2, 2020, the Reporting Person was granted 175,000 restricted stock units.  The vesting of the shares under the restricted stock unit award was to be based on the achievement of a specified amount of 2020 revenues from ZILRETTA product sales established at the time of the Compensation Committee's approval of the restricted stock unit award.  On January 27, 2021, the Compensation Committee certified the achievement of a specified amount of 2020 revenues from ZILRETTA product sales resulting in the commencement of vesting of 119,500 shares. The remaining 55,500 restricted stock units granted to the Reporting Person on March 2, 2020, were forfeited based on the above performance metrics. The Reporting Person previously reported the restricted stock units in Table II of Form 4."}],"balance_after":275677,"source":{"system":"sec-edgar","filing":"0001209191-21-006328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121006328/doc4.xml","form_type":"4"}},{"id":2913588,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-07T17:47:08.000Z","date":"2021-01-05","kind":"tax_withholding","acquired":false,"shares":2530,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on February 1, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on February 1, 2018."}],"balance_after":156177,"source":{"system":"sec-edgar","filing":"0001209191-21-002556","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121002556/doc4.xml","form_type":"4"}},{"id":2913587,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-07T17:47:08.000Z","date":"2020-07-08","kind":"gift","acquired":false,"shares":1303,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 8, 2020, the Reporting Person transferred 1,303 shares of the Issuer's Common Stock to The Michael D.Clayman 2006 Revocable Trust."}],"balance_after":158707,"source":{"system":"sec-edgar","filing":"0001209191-21-002556","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121002556/doc4.xml","form_type":"4"}},{"id":3079501,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-07-20T21:26:56.000Z","date":"2020-07-16","kind":"grant","acquired":true,"shares":93750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. 1/3 of the shares subject to the restricted stock unit award vest on each of July 16, 2021, July 16, 2022 and July 16, 2023."}],"balance_after":160010,"source":{"system":"sec-edgar","filing":"0001209191-20-043111","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120043111/doc4.xml","form_type":"4"}},{"id":3100785,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-24T16:18:53.000Z","date":"2020-06-22","kind":"grant","acquired":true,"shares":1303,"price":10.83,"value":14111.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed voluntarily to report the acquisition of 1,303 shares by the Reporting Person on June 22, 2020 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":66260,"source":{"system":"sec-edgar","filing":"0001209191-20-038727","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120038727/doc4.xml","form_type":"4"}},{"id":3133551,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-27T16:11:48.000Z","date":"2020-05-26","kind":"purchase","acquired":true,"shares":10256,"price":9.75,"value":99996.0,"ownership":{"direct":false,"nature":"By the Michael D.Clayman 2006 Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were purchased in connection with the Issuer's public offering."}],"balance_after":346605,"source":{"system":"sec-edgar","filing":"0001209191-20-032287","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120032287/doc4.xml","form_type":"4"}},{"id":3231880,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit Award","published_at":"2020-03-03T16:10:03.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon confirmation by the Board of Directors or the Compensation Committee of the Board that a specified amount of 2020 revenues from ZILRETTA product sales is achieved, 25% of shares subject to the restricted stock unit award shall vest in 2021 upon such confirmation and thereafter on January 1 of the subsequent three years so that all of such shares will have vested on January 1, 2024."}],"balance_after":175000,"derivative":{"exercise_price":0,"expiration_date":"2024-01-01","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-20-015098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120015098/doc4.xml","form_type":"4"}},{"id":3231879,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2020-03-03T16:10:03.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares shall vest on the one year anniversary of January 1, 2020 (the \"Vesting Commencement Date\") and thereafter one-forty-eighth (1/48th) of the total shares shall vest each month following the one year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four (4) years after the Vesting Commencement Date."}],"balance_after":185000,"derivative":{"exercise_price":15.78,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":185000},"source":{"system":"sec-edgar","filing":"0001209191-20-015098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120015098/doc4.xml","form_type":"4"}},{"id":3316233,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-01-07T17:40:06.000Z","date":"2020-01-07","kind":"gift","acquired":false,"shares":5457,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the Michael D.Clayman 2006 Revocable Trust"},"balance_after":336349,"source":{"system":"sec-edgar","filing":"0001209191-20-002305","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120002305/doc4.xml","form_type":"4"}},{"id":3316232,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-01-07T17:40:06.000Z","date":"2019-10-09","kind":"gift","acquired":true,"shares":10398,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the Michael D.Clayman 2006 Revocable Trust"},"balance_after":330892,"source":{"system":"sec-edgar","filing":"0001209191-20-002305","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120002305/doc4.xml","form_type":"4"}},{"id":3316231,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-01-07T17:40:06.000Z","date":"2020-01-07","kind":"gift","acquired":false,"shares":5457,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":64957,"source":{"system":"sec-edgar","filing":"0001209191-20-002305","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120002305/doc4.xml","form_type":"4"}},{"id":3316230,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-01-07T17:40:06.000Z","date":"2020-01-03","kind":"tax_withholding","acquired":false,"shares":2494,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on February 1, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on February 1, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 659 shares of Common Stock that were acquired by the Reporting Person on December 20, 2019 at $9.89 per share pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":70414,"source":{"system":"sec-edgar","filing":"0001209191-20-002305","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120002305/doc4.xml","form_type":"4"}},{"id":3316229,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-01-07T17:40:06.000Z","date":"2019-10-09","kind":"gift","acquired":false,"shares":10398,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":72249,"source":{"system":"sec-edgar","filing":"0001209191-20-002305","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120002305/doc4.xml","form_type":"4"}},{"id":3395943,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit Award","published_at":"2019-10-08T16:25:20.000Z","date":"2019-10-06","kind":"exercise","acquired":false,"shares":14800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On January 4, 2016, the reporting person was granted up to 66,600 restricted stock units. The amount and vesting of the shares under the restricted stock unit award was based on the achievement of certain milestones that were established at the time of the Compensation Committee's approval of the restricted stock unit award on December 17, 2015.  On October 6, 2017, the Compensation Committee certified the achievement of a milestone under the restricted stock unit award resulting in the commencement of vesting of 44,400 shares as follows:  14,800 shares vested as of October 6, 2017, 14,800 shares vested as of October 6, 2018 and 14,800 shares vested as of October 6, 2019."}],"balance_after":0,"derivative":{"expiration_date":"2019-10-06","underlying":"Common Stock","underlying_shares":14800},"source":{"system":"sec-edgar","filing":"0001209191-19-052754","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119052754/doc4.xml","form_type":"4"}},{"id":3395942,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-10-08T16:25:20.000Z","date":"2019-10-07","kind":"tax_withholding","acquired":false,"shares":4402,"price":13.98,"value":61539.96,"ownership":{"direct":true},"balance_after":82647,"source":{"system":"sec-edgar","filing":"0001209191-19-052754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119052754/doc4.xml","form_type":"4"}},{"id":3395941,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-10-08T16:25:20.000Z","date":"2019-10-06","kind":"exercise","acquired":true,"shares":14800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":87049,"source":{"system":"sec-edgar","filing":"0001209191-19-052754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119052754/doc4.xml","form_type":"4"}},{"id":3443443,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-08-08T16:38:12.000Z","date":"2019-08-08","kind":"purchase","acquired":true,"shares":2317,"price":10.8486,"value":25136.2062,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $10.84860, and the range of prices were between $10.83360 and $10.85090.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":72249,"source":{"system":"sec-edgar","filing":"0001209191-19-045123","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119045123/doc4.xml","form_type":"4"}},{"id":3479991,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-06-24T17:23:26.000Z","date":"2019-06-24","kind":"gift","acquired":true,"shares":1492,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the Michael D. Clayman 2006 Revocable Trust"},"balance_after":320494,"source":{"system":"sec-edgar","filing":"0001209191-19-038817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119038817/doc4.xml","form_type":"4"}},{"id":3479990,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-06-24T17:23:26.000Z","date":"2019-01-28","kind":"gift","acquired":true,"shares":4936,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the Michael D. Clayman 2006 Revocable Trust"},"balance_after":319002,"source":{"system":"sec-edgar","filing":"0001209191-19-038817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119038817/doc4.xml","form_type":"4"}},{"id":3479989,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-06-24T17:23:26.000Z","date":"2019-06-24","kind":"gift","acquired":false,"shares":1492,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":69932,"source":{"system":"sec-edgar","filing":"0001209191-19-038817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119038817/doc4.xml","form_type":"4"}},{"id":3479988,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-06-24T17:23:26.000Z","date":"2019-06-21","kind":"grant","acquired":true,"shares":1492,"price":9.81,"value":14636.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were acquired by the Reporting Person on June 21, 2019 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":71424,"source":{"system":"sec-edgar","filing":"0001209191-19-038817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119038817/doc4.xml","form_type":"4"}},{"id":3479987,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-06-24T17:23:26.000Z","date":"2019-01-28","kind":"gift","acquired":false,"shares":4936,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":69932,"source":{"system":"sec-edgar","filing":"0001209191-19-038817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119038817/doc4.xml","form_type":"4"}},{"id":3529656,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-05-13T09:15:40.000Z","date":"2019-05-10","kind":"purchase","acquired":true,"shares":4012,"price":12.4794,"value":50067.3528,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $12.47940, and the range of prices were between $12.470 and $12.481.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":74868,"source":{"system":"sec-edgar","filing":"0001209191-19-029182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119029182/doc4.xml","form_type":"4"}},{"id":3597000,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-03-13T16:11:48.000Z","date":"2019-03-12","kind":"purchase","acquired":true,"shares":4046,"price":12.36,"value":50008.56,"ownership":{"direct":true},"balance_after":70856,"source":{"system":"sec-edgar","filing":"0001209191-19-019135","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119019135/doc4.xml","form_type":"4"}},{"id":3611870,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2019-03-05T16:23:56.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":360000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"With respect to 290,000 of the shares subject to the option, 25% of such shares shall vest on the one year anniversary of January 1, 2019 (the \"Vesting Commencement Date\") and thereafter 1/48th of such shares shall vest each month following the one year anniversary of the Vesting Commencement Date, so that all such shares shall be vested four years after the Vesting Commencement Date. With respect to 70,000 of the shares subject to the option, if the Company's 2019 revenues from ZILRETTA product sales are at least a specified amount, then 17,500 of such shares shall vest on January 1, 2020 and thereafter 1/48th of such shares shall vest each month following January 1, 2020, so that all of such shares shall be vested four years after January 1, 2019."}],"balance_after":360000,"derivative":{"exercise_price":14.75,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":360000},"source":{"system":"sec-edgar","filing":"0001209191-19-016478","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119016478/doc4.xml","form_type":"4"}},{"id":3703805,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-01-04T17:03:59.000Z","date":"2019-01-03","kind":"sale","acquired":false,"shares":3278,"price":12.36,"value":40516.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares of common stock pursuant to Rule 10b5-1 arrangements to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on February 1, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 922 shares of Common Stock that were acquired by the Reporting Person on December 20, 2018 at $10.48 per share pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":66810,"source":{"system":"sec-edgar","filing":"0001209191-19-002065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119002065/doc4.xml","form_type":"4"}},{"id":3766771,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-11-13T09:17:53.000Z","date":"2018-10-11","kind":"gift","acquired":true,"shares":8567,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the Michael D.Clayman 2006 Revocable Trust"},"balance_after":314066,"source":{"system":"sec-edgar","filing":"0001209191-18-058086","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118058086/doc4.xml","form_type":"4"}},{"id":3766770,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-11-13T09:17:53.000Z","date":"2018-02-27","kind":"gift","acquired":true,"shares":10562,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the Michael D.Clayman 2006 Revocable Trust"},"balance_after":305499,"source":{"system":"sec-edgar","filing":"0001209191-18-058086","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118058086/doc4.xml","form_type":"4"}},{"id":3766769,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-11-13T09:17:53.000Z","date":"2018-06-27","kind":"gift","acquired":true,"shares":554,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the Michael D.Clayman 2006 Revocable Trust"},"balance_after":294937,"source":{"system":"sec-edgar","filing":"0001209191-18-058086","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118058086/doc4.xml","form_type":"4"}},{"id":3766768,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-11-13T09:17:53.000Z","date":"2018-11-09","kind":"purchase","acquired":true,"shares":5000,"price":17.0953,"value":85476.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $17.0953, and the range of prices were between $16.95 and $17.33.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":69166,"source":{"system":"sec-edgar","filing":"0001209191-18-058086","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118058086/doc4.xml","form_type":"4"}},{"id":3766767,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-11-13T09:17:53.000Z","date":"2018-10-11","kind":"gift","acquired":false,"shares":8567,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":64166,"source":{"system":"sec-edgar","filing":"0001209191-18-058086","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118058086/doc4.xml","form_type":"4"}},{"id":3766766,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-11-13T09:17:53.000Z","date":"2018-02-27","kind":"gift","acquired":false,"shares":10562,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":72733,"source":{"system":"sec-edgar","filing":"0001209191-18-058086","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118058086/doc4.xml","form_type":"4"}},{"id":3766765,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-11-13T09:17:53.000Z","date":"2018-06-27","kind":"gift","acquired":false,"shares":554,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":83295,"source":{"system":"sec-edgar","filing":"0001209191-18-058086","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118058086/doc4.xml","form_type":"4"}},{"id":3794282,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit Award","published_at":"2018-10-09T16:31:50.000Z","date":"2018-10-08","kind":"exercise","acquired":false,"shares":14800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On January 4, 2016, the reporting person was granted up to 66,600 restricted stock units. The amount and vesting of the shares under the restricted stock unit award was based on the achievement of certain milestones that were established at the time of the Compensation Committee's approval of the restricted stock unit award on December 17, 2015.  On October 6, 2017, the Compensation Committee certified the achievement of a milestone under the restricted stock unit award resulting in the commencement of vesting of 44,400 shares as follows:  14,800 shares vested as of October 6, 2017, 14,800 shares vested as of October 6, 2018 and 14,800 shares vested as of October 6, 2019."}],"balance_after":14800,"derivative":{"expiration_date":"2019-10-06","underlying":"Common Stock","underlying_shares":14800},"source":{"system":"sec-edgar","filing":"0001209191-18-054525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118054525/doc4.xml","form_type":"4"}},{"id":3794281,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-10-09T16:31:50.000Z","date":"2018-10-08","kind":"tax_withholding","acquired":false,"shares":6233,"price":18.6,"value":115933.8,"ownership":{"direct":true},"balance_after":83849,"source":{"system":"sec-edgar","filing":"0001209191-18-054525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118054525/doc4.xml","form_type":"4"}},{"id":3794280,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-10-09T16:31:50.000Z","date":"2018-10-08","kind":"exercise","acquired":true,"shares":14800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":90082,"source":{"system":"sec-edgar","filing":"0001209191-18-054525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118054525/doc4.xml","form_type":"4"}},{"id":3847344,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-08-10T09:13:35.000Z","date":"2018-08-09","kind":"purchase","acquired":true,"shares":10000,"price":22.33,"value":223300.0,"ownership":{"direct":true},"balance_after":75282,"source":{"system":"sec-edgar","filing":"0001209191-18-046129","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118046129/doc4.xml","form_type":"4"}},{"id":3884934,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-06-22T16:33:29.000Z","date":"2018-06-20","kind":"other","acquired":true,"shares":554,"price":21.22,"value":11755.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed voluntarily to report the acquisition of 554 shares by the Reporting Person on June 20, 2018 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":65282,"source":{"system":"sec-edgar","filing":"0001209191-18-039220","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118039220/doc4.xml","form_type":"4"}},{"id":3892128,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-06-15T12:16:41.000Z","date":"2018-06-14","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the \"Company's\") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the \"Stock Option\").  100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company."}],"balance_after":12500,"derivative":{"exercise_price":11.14,"exercise_date":"2019-06-14","expiration_date":"2028-06-14","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001562180-18-003015","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218018003015/primarydocument.xml","form_type":"4"}},{"id":4079042,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2018-02-02T16:41:13.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":116667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares subject to the option shall vest one year after January 1, 2018; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following the one year anniversary of January 1, 2018, so that all of the shares subject to the option shall be vested four (4) years after January 1, 2018."}],"balance_after":116667,"derivative":{"exercise_price":22.31,"expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":116667},"source":{"system":"sec-edgar","filing":"0001209191-18-006915","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118006915/doc4.xml","form_type":"4"}},{"id":4079041,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-02-02T16:41:13.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":29167,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":64728,"source":{"system":"sec-edgar","filing":"0001209191-18-006915","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118006915/doc4.xml","form_type":"4"}},{"id":4122392,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-12-22T17:05:00.000Z","date":"2017-12-20","kind":"other","acquired":true,"shares":166,"price":16.59,"value":2753.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed voluntarily to report the acquisition of 166 shares by the Reporting Person on December 20, 2017 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":35561,"source":{"system":"sec-edgar","filing":"0001209191-17-067095","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919117067095/doc4.xml","form_type":"4"}},{"id":4167601,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-11-09T09:13:07.000Z","date":"2017-11-08","kind":"purchase","acquired":true,"shares":5000,"price":23.6,"value":118000.0,"ownership":{"direct":true},"balance_after":35395,"source":{"system":"sec-edgar","filing":"0001209191-17-059880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919117059880/doc4.xml","form_type":"4"}},{"id":4188975,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit Award","published_at":"2017-10-10T16:39:56.000Z","date":"2017-10-06","kind":"exercise","acquired":false,"shares":14800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On January 4, 2016, the reporting person was granted up to 66,600 restricted stock units. The amount and vesting of the shares under the restricted stock unit award was based on the achievement of certain milestones that were established at the time of the Compensation Committee's approval of the restricted stock unit award on December 17, 2015.  On October 6, 2017, the Compensation Committee certified the achievement of a milestone under the restricted stock unit award resulting in the commencement of vesting of 44,400 shares as follows:  14,800 shares vested as of October 6, 2017, 14,800 shares vested as of October 6, 2018 and 14,800 shares vested as of October 6, 2019."}],"balance_after":29600,"derivative":{"expiration_date":"2019-10-06","underlying":"Common Stock","underlying_shares":14800},"source":{"system":"sec-edgar","filing":"0001209191-17-056478","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919117056478/doc4.xml","form_type":"4"}},{"id":4188974,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-10-10T16:39:56.000Z","date":"2017-10-06","kind":"tax_withholding","acquired":false,"shares":5794,"price":29.9349,"value":173442.8106,"ownership":{"direct":true},"balance_after":30395,"source":{"system":"sec-edgar","filing":"0001209191-17-056478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919117056478/doc4.xml","form_type":"4"}},{"id":4188973,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-10-10T16:39:56.000Z","date":"2017-10-06","kind":"exercise","acquired":true,"shares":14800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":36189,"source":{"system":"sec-edgar","filing":"0001209191-17-056478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919117056478/doc4.xml","form_type":"4"}},{"id":4273439,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-06-23T18:36:27.000Z","date":"2017-06-20","kind":"other","acquired":true,"shares":1243,"price":15.37,"value":19104.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed voluntarily to report the acquisition of 1,243 shares by the Reporting Person on June  20, 2017 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":21389,"source":{"system":"sec-edgar","filing":"0001209191-17-041751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919117041751/doc4.xml","form_type":"4"}},{"id":4277094,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2017-06-19T20:05:10.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the option shares vest on the first anniversary of the date of grant (the \"Vesting Date\"), provided that the Reporting Person remains in continuous service as a member of the Issuer's Board of Directors through the Vesting Date, and provided further that the options held by the Reporting Person shall be eligible for vesting acceleration upon a \"Change in Control\" as defined and provided for in the Issuer's Non-Employee Director Stock Option Award Agreement."}],"balance_after":12500,"derivative":{"exercise_price":14.37,"exercise_date":"2018-06-15","expiration_date":"2027-06-15","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001562180-17-002293","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017002293/primarydocument.xml","form_type":"4"}},{"id":4291004,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-06-06T18:47:58.000Z","date":"2017-06-05","kind":"purchase","acquired":true,"shares":5000,"price":17.2303,"value":86151.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $17.23030, and the range of prices were between $17.22580 and $17.23980.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":20146,"source":{"system":"sec-edgar","filing":"0001209191-17-038221","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919117038221/doc4.xml","form_type":"4"}},{"id":4390638,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-03-10T17:03:15.000Z","date":"2016-06-21","kind":"gift","acquired":true,"shares":15722,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the Michael D.Clayman 2006 Revocable Trust"},"balance_after":294383,"source":{"system":"sec-edgar","filing":"0001209191-17-019900","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919117019900/doc4.xml","form_type":"4"}},{"id":4390637,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-03-10T17:03:15.000Z","date":"2016-06-21","kind":"gift","acquired":false,"shares":15722,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15146,"source":{"system":"sec-edgar","filing":"0001209191-17-019900","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919117019900/doc4.xml","form_type":"4"}},{"id":4511831,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2016-12-27T16:58:18.000Z","date":"2016-12-20","kind":"other","acquired":true,"shares":147,"price":9.01,"value":1324.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed voluntarily to report the acquisition of 147 shares by the Reporting Person on December 20, 2016 pursuant to the Issuer's Employee Stock Purchase Plan."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 is being filed voluntarily to report the acquisition of 147 shares by the Reporting Person on December 20, 2016 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":30868,"source":{"system":"sec-edgar","filing":"0001209191-16-156827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919116156827/doc4.xml","form_type":"4"}},{"id":4513175,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2016-12-22T16:34:40.000Z","date":"2016-12-20","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest one year after December 20, 2016; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following the one year anniversary of December 20, 2016, so that all of the shares subject to the option shall be vested four (4) years after December 20, 2016."}],"balance_after":175000,"derivative":{"exercise_price":18.56,"expiration_date":"2026-12-19","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-16-156527","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919116156527/doc4.xml","form_type":"4"}},{"id":4542989,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2016-11-23T20:17:20.000Z","date":"2016-11-23","kind":"purchase","acquired":true,"shares":1667,"price":18.4093,"value":30688.3031,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $18.4093, and the range of prices were between $18.13 and $18.60.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":30721,"source":{"system":"sec-edgar","filing":"0001209191-16-152006","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919116152006/doc4.xml","form_type":"4"}},{"id":4542988,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2016-11-23T08:35:31.000Z","date":"2016-11-22","kind":"purchase","acquired":true,"shares":1666,"price":17.9473,"value":29900.2018,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $17.94730, and the range of prices were between $17.76 and $18.08.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":29054,"source":{"system":"sec-edgar","filing":"0001209191-16-151827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919116151827/doc4.xml","form_type":"4"}},{"id":4544871,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":133269,"kind":"person","name":"Clayman Michael D.","position":1,"cik":"0001597407","reported_name":"Clayman Michael D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2016-11-22T14:28:40.000Z","date":"2016-11-21","kind":"purchase","acquired":true,"shares":1666,"price":17.9036,"value":29827.3976,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $17.90360, and the range of prices were between $17.70 and $18.23.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":27388,"source":{"system":"sec-edgar","filing":"0001209191-16-151664","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919116151664/doc4.xml","form_type":"4"}}]}